医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AGC Automotive Window Glass Products Earn The Skin Cancer Foundation’s Seal of Recommendation

2013年10月22日 PM01:55
このエントリーをはてなブックマークに追加


 

TOKYO

AGC, a world-leading manufacturer of glass, chemicals and high-tech materials, announced today that two of its products for automotive windows—UV Verre Premium™ /UV Verre Premium Cool on™ tempered glass and Lamisafe™ laminated glass—have earned The Skin Cancer Foundation’s Seal of Recommendation, a prestigious symbol of safe and effective sun protection.

The UV Verre Premium Series, which consists of UV Verre Premium and UV Verre Premium Cool on, is the first tempered automotive glass of its kind to block approximately 99% of UV rays, which is achieved with a high-performance hybrid organic/inorganic coating on the interior side. The series has gained popularity for use as front-door windows in family-oriented cars in Japan. The UV Verre Premium Series was launched in Japan in December 2010 and was being used in 25 car models as of September 2013. In future, AGC will introduce it in North America and other global markets.

Lamisafe consists of two glass layers and a UV-blocking resin film in between. The design, in addition to blocking up to 99% of UV rays, effectively prevents fragments from scattering during breakage and objects from entering vehicle interiors. Lamisafe is used for the windshield and/or door glass of cars worldwide. Going forward, AGC aims to increase the number of car models that use this product.

The Skin Cancer Foundation is a leading international organization devoted solely to education, prevention, early detection, and prompt treatment of skin cancer. According to the Foundation, more than 3.5 million cases of skin cancer in more than two million people are diagnosed annually in the U.S.

“We spend so much time in our cars, it’s important to make sun protection a priority while driving. Protective window glass is a great addition to a complete sun protection regimen that includes covering up with clothing, wearing a wide-brimmed hat and UV-blocking sunglasses, using a broad spectrum sunscreen with an SPF of 15 or higher and seeking shade”, says Perry Robins, MD, President of The Skin Cancer Foundation.

The AGC Group will continue to develop UV-cut glass solutions, and aims to introduce such products worldwide as quickly as possible to enhance the comfort and convenience of automotive transportation.

Please visit www.skincancer.org for further information on The Skin Cancer Foundation.

About the AGC Group

The AGC Group, with Tokyo-based Asahi Glass Co., Ltd. at its core, is a world-leading supplier of flat, automotive and display glass, chemicals and other high-tech materials and components. Drawing on more than a century of technical innovation, the AGC Group has developed world-class expertise in fields including glass, fluorine chemistry and ceramics technologies. The group employs some 50,000 people worldwide and generates annual sales of approximately 12 billion USD through business in about 30 countries. For more information, please visit www.agc-group.com/en.

Attachment

  1. The Skin Cancer Foundation’s Seal of Recommendation
    AGC’s UV Verre Premium™ Series tempered glass and Lamisafe™ laminated glass both meet The Skin Cancer Foundation standards, and are entitled to bear the following Seal.
    Sun protective products that are eligible for the Seal include: auto and residential glass and window film, sunscreens, sunglasses, awnings/umbrellas, clothing and laundry products.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131021006669/en/

CONTACT

Media Contact
Asahi Glass Co., Ltd.
Toshihiro Ueda,
General Manager, Corporate Communications & Investor Relations
(Contact:
Yasuo Sugiyama; Tel: +81-3-3218-5603; E-mail: info-pr@agc.com)

同じカテゴリーの記事 

  • Poxel to Report Its 2023 Annual Results by the End of April 2024
  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告